Challenges with EGRIFTA SV Supply
Theratechnologies Inc. is currently dealing with a possible supply interruption for EGRIFTA SV, an important treatment for patients. This issue is caused by an unexpected shutdown at its contract manufacturing facility, following an inspection by the U.S. Food and Drug Administration (FDA) that resulted in a voluntary suspension of operations.
Company's Actions During the Disruption
Paul Lévesque, the President and CEO of Theratechnologies, has reassured stakeholders about the company's quick response to the situation. "We are actively collaborating with our manufacturer and the FDA to work through this temporary hurdle," he said. Lévesque's confidence comes from the company's readiness and dedication to minimize the impact on patients throughout 2025.
Managing Inventory Strategically
To tackle potential supply shortages, Theratechnologies has started to put strategic inventory management practices into action. These steps are essential to ensure that EGRIFTA SV stays available for patient needs until early January 2025. However, the company does predict a revenue hit of about US$1.6 million for fiscal year 2024 directly due to the upcoming supply disruptions.
Looking Forward: Financial Considerations
Even though the financial effects of this disruption are significant, Theratechnologies remains hopeful about achieving strong adjusted EBITDA for the current fiscal year. More detailed information regarding these financial outcomes will be shared during the announcement of their third quarter results.
Details Behind the Manufacturing Shutdown
The temporary closure of the manufacturing facility is due to compliance issues noted during an FDA inspection. Importantly, these observations do not relate to the quality of EGRIFTA SV itself but are focused on aspects of the manufacturing environment. The response plan created by the manufacturer is nearing completion, with operations expected to resume by mid-October. A new batch of EGRIFTA SV is scheduled for production on October 21, 2024.
The Regulatory Steps Ahead
The FDA has instructed Theratechnologies to file a Prior Approval Supplement (PAS) detailing the changes made by its contract manufacturer. The company intends to submit this supplement around the time of the planned manufacturing date. Once submitted, the FDA usually reviews it within a four-month period, which will provide guidance and support for the resumption of distribution.
The Importance of EGRIFTA SV
EGRIFTA SV is a vital treatment option for certain patients, making access to it essential. Currently, it is only available in the United States, but it plays a key role in addressing significant health needs for individuals requiring effective management of their conditions.
Updates from Theratechnologies
The company is committed to keeping stakeholders informed about any important updates related to this situation. As they continue to collaborate with the FDA and their manufacturing partner, Theratechnologies will provide information to ensure everyone is aware of the changing circumstances.
Frequently Asked Questions
What is EGRIFTA SV?
EGRIFTA SV is a biopharmaceutical treatment developed by Theratechnologies for specific medical conditions that need targeted therapy.
Why did the supply disruption occur?
The supply disruption occurred due to a voluntary shutdown at the manufacturing facility, following compliance issues identified during an FDA inspection.
How is Theratechnologies managing the supply issue?
The company is working closely with their manufacturer and the FDA to resolve the disruption and has introduced inventory management strategies to reduce the impact on patients.
When is the expected resume date for production?
Production is expected to restart by mid-October, with the next batch of EGRIFTA SV anticipated to be produced soon after.
What financial impact is expected from this disruption?
Theratechnologies projects a revenue shortfall of roughly US$1.6 million for fiscal year 2024 due to the expected supply issues.
